Avian Flu Drug Zanamivir Clears SFDA For Clinical Trials
This article was originally published in PharmAsia News
A bird flu drug developed by Shanghai Institute of Materia Medica, Nanjing Xian Sheng Dong Yuan Pharmaceutical and Nanjing Yifang Center for Pharmaceutical R&D have passed preclinical appraisal of China's State FDA Center for Drug Evaluation. The zanamivir capsule and its raw material drug received SFDA's approval Nov. 7 to enter clinical trials. Zanamivir, a neuraminidase inhibitor for the treatment of influenza caused by type A virus, is the second most effective avian flu drug after oseltamivir. (Click here for more - Chinese Language)
You may also be interested in...
While Novartis is continuing to provide hydroxychloroquine for ongoing investigator-initiated trials and support for study of a potential vaccine, it has decided to stop sponsoring hydroxychloroquine clinical trials. Meanwhile, Natco has announced donations of chloroquine phosphate for clinical trials, while Centrient and Beximco have provided PPE for healthcare workers.
New chief medical officers take up positions at Abeona Therapeutics, Akcea Therapeutics and Oncologie, while there are new CFOs at Affimed, NGM Biopharmaceuticals, Phathom Pharmaceuticals, Oncologie and Syndax Pharmaceuticals.
Consumers in the UK can now self-select a version of Infirst's lipid-driven ibuprofen Flarin brand.